Accessibility Menu
Oyster Point Pharma, Inc. logo

Oyster Point Pharma, Inc.(NASDAQ) OYST

This security has been delisted. This page is retained for historical reference.

Oyster Point Pharma, Inc. last closing stock price
MetricPriceDate
Last closeUSD 11.172022-12-30
Oyster Point Pharma, Inc. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.36%USD 11.132022-12-23
1 month-0.09%USD 11.182022-11-30
3 month+98.75%USD 5.622022-09-30
Year to date-38.83%USD 18.262021-12-31
1 year-41.09%USD 18.962021-12-30
3 year-54.3%USD 24.442019-12-31
Since inception-40.52%USD 18.782019-10-31

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

OYST Financials

Key Financial Metrics (TTM)

Gross Margin

93.79%

Operating Margin

-394.98%

Net Income Margin

-425.42%

Return on Equity

-72.95%

Return on Capital

-50.41%

Return on Assets

-46.89%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$15.07M

Operating Income

-$164.32M

EBITDA

-$164.01M

Operating Cash Flow

-$165.98M

Capital Expenditure

-$438.00K

Free Cash Flow

-$166.42M

Cash & ST Invst.

$68.80M

Total Debt

$94.72M

Oyster Point Pharma, Inc. Performance Analysis

Oyster Point Pharma, Inc. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 24,539,000N/A
Oyster Point Pharma, Inc. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31-63.2%
Q12022-03-31-59.0%
Q22022-06-3073.6%
Q32022-09-3019.1%
Oyster Point Pharma, Inc. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -3.87N/A
Oyster Point Pharma, Inc. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31-151.5%
Q12022-03-31-11.7%
Q22022-06-30-4.2%
Q32022-09-3024.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2022YOY CHG

Revenue

$5.59M

-68.8%

Gross Profit

$4.24M

-76.4%

Gross Margin

75.89%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

303

N/A

Net Income

-$40.24M

-127.7%

EBITDA

-$33.18M

-101.0%

Quarterly Fundamentals

Name
Q3 2022YOY CHG

Total Cash

$68.80M

-62.6%

Total Debt

$94.72M

+122.5%

Accounts Receivable

$13.18M

+427.4%

Inventory

$6.96M

N/A

Long Term Debt

$94.03M

+123.4%

Short Term Debt

$692.00K

+43.9%

Return on Assets

-46.89%

N/A

Return on Invested Capital

-50.01%

N/A

Free Cash Flow

-$35.97M

-225.1%

Operating Cash Flow

-$35.97M

-232.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SCPHscPharmaceuticals Inc.
$5.67+0.00%
TSVT2seventy bio, Inc.
$5.00+0.00%
INZYInozyme Pharma, Inc.
$4.00+0.25%
CLYMClimb Bio, Inc.
$12.56+6.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
EAElectronic Arts
$209.70-0.00%
SPCXSpace Exploration Technologies
$125.33+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.26-0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.07+0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.